Publication
Global blood pressure screening during the COVID-19 pandemic: results from the May Measurement Month 2021 campaign
Downloadable Content
- Persistent URL
- Last modified
- 06/25/2025
- Type of Material
- Authors
- Language
- English
- Date
- 2023-09-01
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Publication Version
- Copyright Statement
- © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
- License
- Final Published Version (URL)
- Title of Journal or Parent Work
- Volume
- 41
- Issue
- 9
- Start Page
- 1446
- End Page
- 1455
- Grant/Funding Information
- May Measurement Month (MMM) was an initiative of the International Society of Hypertension. MMM 2021 was generously supported by Servier through the Institut la Conference Hippocrate and USASCP. As a supporter of the study, Servier had no role in study design, data collection, data analysis, data interpretation or writing of the report. The first and corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
- Supplemental Material (URL)
- Abstract
- Background:Raised blood pressure (BP) remains the biggest risk factor contributing to the global burden of disease and mortality, despite the COVID-19 pandemic. May Measurement Month (MMM), an annual global screening campaign aims to highlight the importance of BP measurement by evaluating global awareness, treatment and control rates among adults with hypertension. In 2021, we assessed the global burden of these rates during the COVID-19 pandemic.Methods:Screening sites were set up in 54 countries between May and November 2021 and screenees were recruited by convenience sampling. Three sitting BPs were measured, and a questionnaire completed including demographic, lifestyle and clinical data. Hypertension was defined as a systolic BP at least 140 mmHg and/or a diastolic BP at least 90 mmHg (using the mean of the second and third readings) or taking antihypertensive medication. Multiple imputation was used to impute the average BP when readings were missing.Results:Of the 642 057 screenees, 225 882 (35.2%) were classified as hypertensive, of whom 56.8% were aware, and 50.3% were on antihypertensive medication. Of those on treatment, 53.9% had controlled BP (<140/90 mmHg). Awareness, treatment and control rates were lower than those reported in MMM campaigns before the COVID-19 pandemic. Minimal changes were apparent among those testing positive for, or being vaccinated against COVID-19. Of those on antihypertensive medication, 94.7% reported no change in their treatment because of the COVID-19 pandemic.Conclusion:The high yield of untreated or inadequately treated hypertension in MMM 2021 confirms the need for systematic BP screening where it does not currently exist.
- Author Notes
- Keywords
- Research Categories
- Biology, Neuroscience
- Health Sciences, Public Health
- Psychology, Behavioral
Tools
- Download Item
- Contact Us
-
Citation Management Tools
Relations
- In Collection:
Items
| Thumbnail | Title | File Description | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|---|
|
|
Publication File - w87ns.pdf | Primary Content | 2025-06-04 | Public | Download |